Clinical Trials
24 trialsNCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT07463313 2026-03-11
6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2/3 Not yet recruiting
NCT01025089 2026-01-07
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04224337 2025-12-31
Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma
Seoul National University Hospital
Phase 2 Completed
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT04213794 2025-02-20
TOASTIT
Mayo Clinic
Phase EARLY_PHASE1 Terminated
NCT00856037 2023-09-26
Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer
University of Nebraska
Phase 1 Completed
NCT02566993 2021-10-28
ATLANTIS
PharmaMar
Phase 3 Completed
NCT00859495 2020-08-25
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Columbia University
Phase 2 Terminated
NCT00036790 2019-12-17
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
University of Wisconsin, Madison
Phase 1 Completed
NCT00483509 2019-10-04
NGR007
AGC Biologics S.p.A.
Phase 2 Completed
NCT02261805 2018-04-23
A Phase I/II Study of Ganetespib in Combination With Doxorubicin
Georgetown University
Phase 1/2 Terminated
NCT00634205 2015-02-12
Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma
European Lung Cancer Working Party
Phase 2 Completed
NCT00759824 2015-02-12
A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
European Lung Cancer Working Party
Phase 2 Completed
NCT00024271 2014-01-06
Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00002822 2013-12-19
Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003364 2013-12-19
Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003034 2013-11-06
ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00003696 2013-09-17
Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00003847 2013-09-05
VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer
Vertex Pharmaceuticals Incorporated
Phase 2 Terminated
NCT00002608 2013-07-10
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00004930 2013-06-19
Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00020124 2012-03-15
Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00002858 2009-02-09
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Unknown